Classifying aging as a disease – it’s all about the ‘how’

Latest articles

Ovarian aging – it’s time to menopause for thought

It's World Menopause Day – time to focus on the future of ovarian longevity, not dwell in the present. World Menopause Day is held every...

At-home blood test powers personalised longevity advice

AgeRate develops proprietary DNA methylation clock and mobile app solution to offer users personalised longevity support. Canadian startup AgeRate is aiming to shake up the...

Researchers find warning signs for dementia in the blood

Levels of certain microRNAs indicate risk for cognitive decline. Researchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the...

VIDEO: The Science of Ovarian Longevity

Instead of papering over the cracks of declining fertility and the effects of menopause, what else can we do to help the longevity of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Ovarian aging – it’s time to menopause for thought

It's World Menopause Day – time to focus on the future of ovarian longevity, not dwell in the present. World Menopause Day is held every...

At-home blood test powers personalised longevity advice

AgeRate develops proprietary DNA methylation clock and mobile app solution to offer users personalised longevity support. Canadian startup AgeRate is aiming to shake up the...

Researchers find warning signs for dementia in the blood

Levels of certain microRNAs indicate risk for cognitive decline. Researchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the...

Click the globe for translations.

The hurdle of classifying aging as a disease, rather than an inevitability, has started to be overcome. Now Alex Zhavoronkov is pushing for us to examine how and when this classification should be implemented in order to overcome the “inherent challenges”.

Nearly two years ago, the World Health Organisation (WHO) released the 11th edition of its International Classification of Diseases, and it contained a short entry that constituted a big deal in the Longevity world: “Code MG2A: Old age.”

Aging is a disease and medicine and healthcare should work to prevent it and to slow it. Although the US Food and Drug Administration (FDA) does not currently regulate any therapies designed to address aging, the landscape is beginning to shift away from illness and fixing individual conditions toward increased healthspan, which leads to lifespan.

A letter from Alex Zhavoronkov, CEO of Insilico Medicine, was published in Science today. Dr Zhavoronkov argues that classifying aging as a disease is not enough to give the pharmaceutical industry the impetus to tackle it.

He points out: “Multiple studies suggest that aging starts in utero and staging of most senescence processes will require massive longitudinal studies in humans and animals. Furthermore, the first clinical trials targeting aging, such as Targeting Aging with Metformin (TAME), are under discussion, and no aging biomarker consensus or hierarchical structuring has yet emerged.”

“The concept of staging senescence does not fit the current ICD framework. The addition would likely require a new international initiative to develop a comprehensive set of biomarkers and interventions for senescence and longevity, as well as a set of recommendations for reducing the burden of senescence and aging-associated diseases,” he adds.

Dr Zhavoronkov concludes: “To accelerate drug development efforts focused on aging as a disease in the pharmaceutical industry, we need to demonstrate that basic research into whether aging is a biological process disease can yield valuable targets or interventions that demonstrate efficacy in treating or preventing age-related diseases.”

Although the response from Dr Stuart Calimport et al disagrees with Dr Z about the responsiveness of WHO ICD submissions, it agrees that: “Staging systems are usually developed and maintained by international disease-specific medical societies. We would welcome the development of international initiatives to develop a comprehensive set of staging systems, biomarkers, and interventions for senescence and aging-related diseases.”

At Longevity.Technology we think that delving into the how and the when of classifying aging can only be a good thing. Understanding something is the key to being able to mitigate it – both its cause and its effects – and provide confidence to investors.

Image courtesy of Insilico Medicine

 

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

$70m collaboration to redefine aging research

Astera Institute and Buck Institute announce $70 million collaboration to redefine the field of research on aging. The Buck Institute for Research on Aging and...

A new approach to reversing tissue aging

Exploring Revel’s enzyme-based approach to breaking down crosslinks and targeting tissue aging. Last year, a startup called Revel Pharmaceuticals emerged from the labs at Yale...

Rejuveron leads €15.7m series B in Rejuvenate Biomed

Investment in Rejuvenate Biomed set to accelerate clinical development of its sarcopenia treatment for healthy aging. Rejuveron Life Sciences, a Zürich-based biotechnology company developing therapies...

Ovarian aging – your questions answered

Ovarian longevity and the significance of ovarian aging is poorly understood – our video aims to change that. Join our Scientific Editor Daragh Campbell as...

Learning lessons from clinical trial failure

Metabesity 2021: Joan Mannick talks longevity scientific breakthroughs, healthspan endpoints, her new role at Life Biosciences, and what can be learned from resTORbio’s clinical...